GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Apricus Biosciences Inc (APRI) [hlAlert]

Rating:
Neutral APRI
down 92.85 %

Apricus Biosciences Inc (APRI) downgraded to Neutral with price target $1.50 by ROTH Capital

Posted on: Friday,  Nov 6, 2015  9:25 AM ET by Roth Capital

Roth Capital rated Neutral Apricus Biosciences Inc (NASDAQ: APRI) on 11/06/2015. Previously Roth Capital rated Buy Apricus Biosciences Inc (NASDAQ: APRI) on
03/25/2008., when the stock price was $18.90. Since then, Apricus Biosciences Inc has lost 92.86% as of 11/06/2015's recent price of $1.35.
If you would have followed the previous Roth Capital's recommendation on APRI, you would have lost 92.85% of your investment in 2782 days.

NexMed, Inc. is a pharmaceutical and medical technology company. They develop and commercialize therapeutic products based on proprietary delivery systems. They are currently focusing their efforts on new and patented pharmaceutical products based on a penetration enhancement topical delivery technology known as NexACT(R), which may enable an active drug to be better absorbed through the skin.

ROTH researches emerging growth equities in the media, technology, telecommunications, healthcare, consumer, energy and industrial sectors. The research is focused on companies with market capitalization of between $100 million - $1 billion. Our coverage universe includes approximately 180 small cap growth companies around the globe including several companies from China. With an average market cap of approximately $500 million, our objective is to identify rapidly growing companies with significant long term growth prospects.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/6/2015 9:25 AM Hold
None
1.35 1.50
as of 8/27/2015
1 Week up  1.65 %
1 Month down  -26.34 %
3 Months down  -14.58 %
1 YTD down  -53.58 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/25/2008 8:25 AM Buy
None
18.90 37.50

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy